Clinical Factors Associated With Resistance to Microvascular Complications in Diabetic Patients of Extreme Disease Duration
Hillary A. Keenan(Joslin Diabetes Center), George L. King(Joslin Diabetes Center), Alessandro Doria(Harvard University), Joseph Coney(Joslin Diabetes Center), Lloyd Paul Aiello(Joslin Diabetes Center), Tina Costacou(University of Pittsburgh), Trevor J. Orchard(University of Pittsburgh), Jerry Cavellerano(Joslin Diabetes Center), Jennifer K. Sun(Joslin Diabetes Center)
Cited by 195
Related Papers
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Retinopathy in Diabetes
|Diabetes Care|2004|1.1k
Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications
|Circulation Research|2010|979